Melbourne researchers are helping expand options for people with high cholesterol that puts them at risk of heart attack or stroke, including world-first drugs for potentially deadly conditions.

The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...

Eli Lilly LLY announced that its investigational oral, once-daily cholesterol-lowering drug muvalaplin reduced lipoprotein(a) ...

Excess cholesterol is known to form artery-clogging plaques that can lead to stroke, arterial disease, heart attack, and more, making it the focus of many heart health campaigns.

Dr Eric Berg DC is a ketosis and intermittent fasting expert, and he has shared the many benefits of turmeric, as well as how ...

Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop ...

Dr Eric Berg DC, who is known as The Knowledge Doc, has shared the 'amazing benefits' of taking half a teaspoon of a ...

Since the discovery of statins and the Scandinavian Simvastatin Survival Study (4S) results three decades ago, remarkable advances have been made in the treatment of dyslipidaemia, a major risk factor ...

“This drug is a game-changer,” Prof Nicholls said. “Not only do we have an option for lowering an elusive form of cholesterol ...

One is an siRNA biologic, the other an oral agent, but both lowered Lp(a) levels by 80% or more in ASCVD patients.

A clinical trial testing muvalaplin, a novel oral medication, was able to safely and effectively lower high levels of ...

The highest dose of an experimental pill developed by Eli Lilly dramatically lowered an inherited form of high cholesterol in a mid-stage trial, according to data presented at a medical meeting on ...